In July-September 2020, the pharmaceutical company Teva increased sales of the antibiotic with active substance Azithromycin in Ukraine, which accounts for about 11% of its total sales in the country in monetary terms, by 5% compared to the same period in 2019 of the year.
Teva-Ukraine pharmaceutical company told Interfax-Ukraine that since the beginning of the pandemic in Ukraine Teva has sold more than 600,000 packages of this antibiotic.
At the same time, according to the results of the third quarter of 2020, sales in general on the Ukrainian pharmaceutical market in the segment of oral antibiotics in monetary terms grew by 14% compared to the same period in 2019.
Teva-Ukraine said that the company produces both original and generic azithromycin, which is used to treat bacterial respiratory tract infections and other infectious diseases.
Azithromycin is included in the protocol for providing medical care for COVID-19 in Ukraine and in many countries around the world.
“Teva has been providing uninterrupted supplies of azithromycin to Ukraine since the beginning of the pandemic and we will continue doing this,” the company said.
The company said that demand for azithromycin has grown worldwide amid seasonal illnesses and the use of azithromycin for the treatment of co-infections with COVID-19.
“It is possible that certain dosages and forms of production from different manufacturers may be in short supply. In our case, we do not see risks, since Teva’s portfolio contains 17 trade names of azithromycin, most of them are interchangeable. In case of a possible shortage of one of the forms, we proactively warn our partners about this, talk about available alternative forms of production, increase the volume of their imports,” the company said.
At the same time, Teva urges people to remember the rules for using antibiotics and the possible consequences of irrational antibiotic therapy and self-treatment in general.
“Only a doctor can prescribe antibiotics,” the company said.
According to Proxima Research, Azithromycin Teva has been the leader in the oral antibiotics segment in Ukraine since 2019. Over the past month, its share of all medicines in Ukraine amounted to almost 1% in monetary terms.
Teva Ukraine LLC is one of the five largest pharmaceutical companies on the Ukrainian market. The company’s portfolio includes more than 200 generic and original medicines used in most key therapeutic areas.
Teva Ukraine is part of Teva Pharmaceutical Industries Ltd, an international pharmaceutical company headquartered in Israel, founded in 1901. Teva specializes in the development, production and marketing of generic and original medicines and active pharmaceutical ingredients.